Abstract
Pharmacologic approaches that diminish dopamine-mediated neural transmission in brain have antipsychotic actions in humans. Blockade of D2 family dopamine receptors is the most common strategy. A paradoxical strategy of using dopamine agonists in particular circumstances to similarly diminish dopaminergic transmission is based on the known function of dopamine autoreceptors and on consideration of the intrinsic activity of dopamine agonists. It was apomorphine that first suggested the effectiveness of dopamine agonist treatment for schizophrenia. Now a partial dopamine agonist aripiprazole has come to market for psychosis and others are in development. This chapter reviews the clinical pharmacology of partial dopamine agonists and their development for the treatment of schizophrenia.
Keywords: affinity, intrinsic activity, apomorphine, n-propyl-noraporphine, 3ppp aripiprazole
Current Neuropharmacology
Title: Partial Dopamine Agonists and the Treatment of Psychosis
Volume: 3 Issue: 1
Author(s): Carol A. Tamminga
Affiliation:
Keywords: affinity, intrinsic activity, apomorphine, n-propyl-noraporphine, 3ppp aripiprazole
Abstract: Pharmacologic approaches that diminish dopamine-mediated neural transmission in brain have antipsychotic actions in humans. Blockade of D2 family dopamine receptors is the most common strategy. A paradoxical strategy of using dopamine agonists in particular circumstances to similarly diminish dopaminergic transmission is based on the known function of dopamine autoreceptors and on consideration of the intrinsic activity of dopamine agonists. It was apomorphine that first suggested the effectiveness of dopamine agonist treatment for schizophrenia. Now a partial dopamine agonist aripiprazole has come to market for psychosis and others are in development. This chapter reviews the clinical pharmacology of partial dopamine agonists and their development for the treatment of schizophrenia.
Export Options
About this article
Cite this article as:
Tamminga A. Carol, Partial Dopamine Agonists and the Treatment of Psychosis, Current Neuropharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570159052773404
DOI https://dx.doi.org/10.2174/1570159052773404 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antipsychotics and Cognitive Functioning: A Critical Review
Current Psychopharmacology Ion Channel Defects in Idiopathic Epilepsies
Current Pharmaceutical Design Clinical Potential of Yi-Gan San (Yokukansan) for the Treatment of Psychiatric Disorders
Current Psychiatry Reviews Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Design and Synthesis of Dopaminergic Agonists
Current Medicinal Chemistry Proceedings of the Regional Conference of the International Society for Adolescent Psychiatry and Psychology (ISAPP), a Joint Conference with 18<sup>th</sup> National Symposium of Adolescent Mental Health, Ankara, Turkey, November 21-24, 2013<sup>1</sup>
Adolescent Psychiatry Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
CNS & Neurological Disorders - Drug Targets Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy Gender Differences in Pharmacokinetics and Side Effects of Second Generation Antipsychotic Drugs
Current Neuropharmacology Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Current Medicinal Chemistry Current Therapy and Computational Drug Designing Approaches for Neurodegenerative Diseases -with Focus on Alzheimer’s and Parkinson’s.
Current Signal Transduction Therapy Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Antipsychotics in the Treatment of Impulsivity in Personality Disorders and Impulse Control Disorders
Current Psychopharmacology Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinsons Disease
Current Clinical Pharmacology Systems Biology and Synthetic Biology: Understanding Biological Complexity on the Critical Path to Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Schizophrenia: Redox Regulation and Volume Neurotransmission
Current Neuropharmacology Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology